83 FR 22501 - National Institute of General Medical Sciences; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 94 (May 15, 2018)

Page Range		22501-22502
FR Document		2018-10356

Federal Register, Volume 83 Issue 94 (Tuesday, May 15, 2018)

[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Pages 22501-22502]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-10356]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the

[[Page 22502]]

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of Support of Competitive 
Research (SCORE) Award Applications.
    Date: July 12, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.
    Contact Person: Saraswathy Seetharam, Scientific Review Officer, 
Office Scientific Review, National Institute of General Medical 
Sciences, National Institutes Health, 45 Center Drive, Room 3AN12C, 
Bethesda, MD 20892, 301-594-2763, seetharams@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives; 93.859, Biomedical Research and 
Research Training, National Institutes of Health, HHS)

    Dated: May 10, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-10356 Filed 5-14-18; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices 22501

DEPARTMENT OF HEALTH AND 6. PCT Patent Application No. PCT/ important role as a major intrinsic
HUMAN SERVICES 2007/080647, filed October 5, 2007, now vasodilator, and increases blood flow to
abandoned (HHS Ref. No. E–227–2006/ tissues and organs. Disruption of this
National Institutes of Health 5–PCT–01); process leads to peripheral vascular
7. U.S. Patent No. 8,236,313, filed disease, ischemic heart disease, stroke,
Prospective Grant of an Exclusive April 3, 2009, Issued August 7, 2012 diabetes and many more significant
Patent License: Use of the CD47 (HHS Ref. No. E–227–2006/5–US–02); diseases. The inventors have discovered
Phosphorodiamidate Morpholino 8. Canadian Patent Application No. that TSP1 blocks the beneficial effects of
Oligomers for the Treatment, 2,665,287, October 5, 2007 (HHS Ref. NO, and prevents it from dilating blood
Prevention, and Diagnosis of No. E–227–2006/5–CA–03); vessels and increasing blood flow to
Hematological Cancers 9. Australian Patent No. 2007319576, organs and tissues. Additionally, they
AGENCY: National Institutes of Health, filed October 5, 2007, Issued May 1, discovered that this regulation requires
HHS. 2014 (HHS Ref. No. E–227–2006/5–AU– TSP1 interaction with its cell receptor,
04); CD47. These inventors have also found
ACTION: Notice. 10. European Patent Application No. that blocking TSP1–CD47 interaction
SUMMARY: The National Cancer Institute, 07868382.8, filed March 27, 2009 (HHS through the use of antisense morpholino
an institute of the National Institutes of Ref. No. E–227–2006/5–EP–05); oligonucleotides, peptides, or antibodies
Health, Department of Health and 11. U.S. Patent Application No. 13/ has several therapeutic benefits
Human Services, is contemplating the 546,931, filed July 11, 2012 (HHS Ref. including the treatment of cancer.
grant of an Exclusive Patent License to No. E–227–2006/5–US–06); This notice is made in accordance
practice the inventions embodied in the 12. U.S. Patent Number 8,557,788, with 35 U.S.C. 209 and 37 CFR part 404.
Patents and Patent Applications listed filed July 11, 2012, Issued October 15, The prospective exclusive license will
in the Supplementary Information 2013 (HHS Ref. No. E–227–2006/5–US– be royalty bearing, and the prospective
section of this notice to Morphiex 07); exclusive license may be granted unless
Biotherapeutics (‘‘Morphiex’’) located in 13. European Patent Application No. within fifteen (15) days from the date of
Boston, MA. 13180563.2, filed October 5, 2007 (HHS this published notice, the National
Ref. No. E–227–2006/5–EP–08); Cancer Institute receives written
DATES: Only written comments and/or 14. Australian Patent No. 2014201936,
applications for a license which are evidence and argument that establishes
filed October 5, 2007, Issued October 20, that the grant of the license would not
received by the National Cancer 2016 (HHS Ref. No. E–227–2006/5–AU–
Institute’s Technology Transfer Center be consistent with the requirements of
09); 35 U.S.C. 209 and 37 CFR part 404.
on or before May 30, 2018 will be 15. U.S. Patent Application No. 14/
considered. In response to this Notice, the public
500,861, filed September 29, 2014 (HHS may file comments or objections.
ADDRESSES: Requests for copies of the Ref. No. E–227–2006/5–US–10); Comments and objections, other than
patent application, inquiries, and 16. Australian Patent No. 2016238894, those in the form of a license
comments relating to the contemplated filed October 6, 2016, Issued February application, will not be treated
an Exclusive Patent License should be 22, 2018 (HHS Ref. No. E–227–2006/5– confidentially, and may be made
directed to: Jaime M. Greene, Senior AU–11); publicly available.
Licensing and Patenting Manager, NCI 17. Australian Patent Application No. License applications submitted in
Technology Transfer Center, 9609 2018200921, filed February 8, 2018 response to this Notice will be
Medical Center Drive, RM 1E530 MSC (HHS Ref. No. E–227–2006/5–AU–12). presumed to contain business
9702, Bethesda, MD 20892–9702 (for The patent rights in these inventions
confidential information and any release
business mail), Rockville, MD 20850– have been assigned and/or exclusively
of information in these license
9702 Telephone: (240) 276–5530; licensed to the government of the
applications will be made only as
Facsimile: (240)–276–5504 Email: United States of America.
required and upon a request under the
greenejaime@mail.nih.gov. The prospective exclusive license
Freedom of Information Act, 5 U.S.C.
SUPPLEMENTARY INFORMATION: territory may be worldwide and the
552.
field of use may be limited to ‘‘the use
Intellectual Property of the CD47 phosphorodiamidate Dated: April 30, 2018.
1. U.S. Provisional Patent Application morpholino oligomers (PMO, Richard U. Rodriguez,
No. 60/850,132, filed October 6, 2006, morpholino, Sequence: 5′- Associate Director, Technology Transfer
now abandoned (HHS Ref. No. E–227– CGTCACAGGCAGGACCCACTGCCCA- Center, National Cancer Institute.
2006/0–US–01); 3′) for the treatment, prevention, and [FR Doc. 2018–10238 Filed 5–14–18; 8:45 am]
2. U.S. Provisional Patent Application diagnosis of hematological cancers (e.g. BILLING CODE 4140–01–P
No. 60/864,153, filed November 02, lymphoma, leukemia, multiple
2006, now abandoned (HHS Ref. No. E– myeloma), excluding uses in
227–2006/1–US–01); combination with radiotherapy.’’ DEPARTMENT OF HEALTH AND
3. U.S. Provisional Patent Application This technology concerns CD47, HUMAN SERVICES
No. 60/888,754, filed February 07, 2007, originally named integrin-associated
now abandoned (HHS Ref. No. E–227– protein, which is a receptor for National Institutes of Health
2006/2–US–01); thrombospondin-1(TSP–1), a major
component of platelet a-granules from National Institute of General Medical
4. U.S. Provisional Patent Application
daltland on DSKBBV9HB2PROD with NOTICES

which it is secreted on platelet Sciences; Notice of Closed Meeting
No. 60/910,549, filed April 06, 2007,
now abandoned (HHS Ref. No. E–227– activation. A number of important roles Pursuant to section 10(d) of the
2006/3–US–01); for CD47 have been defined in Federal Advisory Committee Act, as
5. U.S. Provisional Patent Application regulating the migration, proliferation, amended, notice is hereby given of the
No. 60/956,375, filed August 16, 2007, and survival of vascular cells, and in following meeting.
now abandoned (HHS Ref. No. E–227– regulation of innate and adaptive The meeting will be closed to the
2006/4–US–01); immunity. Nitric Oxide (NO) plays an public in accordance with the

VerDate Sep<11>2014 20:27 May 14, 2018 Jkt 244001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\15MYN1.SGM 15MYN1

22502 Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices

provisions set forth in sections would constitute a clearly unwarranted Democracy 1, Room 1080, Bethesda, MD
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. 20892–4874, nelsonbj@mail.nih.gov.
as amended. The grant applications and (Catalogue of Federal Domestic Assistance
Name of Committee: National Institute on
the discussions could disclose Program Nos. 93.859, Pharmacology,
Aging Special Emphasis Panel; Training
confidential trade secrets or commercial Physiology, and Biological Chemistry
Grants. Research; 93.350, B—Cooperative
property such as patentable material, Date: June 8, 2018. Agreements; 93.859, Biomedical Research
and personal information concerning Time: 3:00 p.m. to 5:30 p.m. and Research Training, National Institutes of
individuals associated with the grant Agenda: To review and evaluate contract Health, HHS)
applications, the disclosure of which proposals.
would constitute a clearly unwarranted Place: National Institute on Aging, Dated: May 9, 2018.
Gateway Building, Suite 2W200, 7201 David D. Clary,
invasion of personal privacy. Wisconsin Avenue, Bethesda, MD 20892.
Name of Committee: National Institute of Contact Person: Jeannette L. Johnson, Program Analyst, Office of Federal Advisory
General Medical Sciences Special Emphasis Ph.D., National Institutes on Aging, National Committee Policy.
Panel; Review of Support of Competitive Institutes of Health, 7201 Wisconsin Avenue, [FR Doc. 2018–10234 Filed 5–14–18; 8:45 am]
Research (SCORE) Award Applications. Suite 2C212, Bethesda, MD 20892, 301–402– BILLING CODE 4140–01–P
Date: July 12, 2018. 7705, johnsonj9@nia.nih.gov.
Time: 8:00 a.m. to 5:00 p.m. (Catalogue of Federal Domestic Assistance
Agenda: To review and evaluate grant Program Nos. 93.866, Aging Research, DEPARTMENT OF HEALTH AND
applications. National Institutes of Health, HHS) HUMAN SERVICES
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814. Dated: May 10, 2018.
National Institutes of Health
Contact Person: Saraswathy Seetharam, Melanie J. Pantoja,
Scientific Review Officer, Office Scientific Program Analyst, Office of Federal Advisory National Institute of Dental and
Review, National Institute of General Medical Committee Policy. Craniofacial Research; Notice of
Sciences, National Institutes Health, 45 [FR Doc. 2018–10353 Filed 5–14–18; 8:45 am] Closed Meetings
Center Drive, Room 3AN12C, Bethesda, MD BILLING CODE 4140–01–P
20892, 301–594–2763, seetharams@ Pursuant to section 10(d) of the
nigms.nih.gov. Federal Advisory Committee Act, as
(Catalogue of Federal Domestic Assistance DEPARTMENT OF HEALTH AND amended, notice is hereby given of the
Program Nos. 93.375, Minority Biomedical following meetings.
HUMAN SERVICES
Research Support; 93.821, Cell Biology and The meetings will be closed to the
Biophysics Research; 93.859, Pharmacology, public in accordance with the
National Institutes of Health
Physiology, and Biological Chemistry provisions set forth in sections
Research; 93.862, Genetics and
National Center for Advancing 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96, Translational Sciences; Notice of as amended. The grant applications and
Special Minority Initiatives; 93.859, Closed Meeting the discussions could disclose
Biomedical Research and Research Training, confidential trade secrets or commercial
Pursuant to section 10(d) of the property such as patentable material,
National Institutes of Health, HHS)
Federal Advisory Committee Act, as and personal information concerning
Dated: May 10, 2018. amended, notice is hereby given of the individuals associated with the grant
Melanie J. Pantoja, following meeting. applications, the disclosure of which
Program Analyst, Office of Federal Advisory The meeting will be closed to the would constitute a clearly unwarranted
Committee Policy. public in accordance with the invasion of personal privacy.
[FR Doc. 2018–10356 Filed 5–14–18; 8:45 am] provisions set forth in sections
BILLING CODE 4140–01–P 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Name of Committee: National Institute of
Dental and Craniofacial Research Special
as amended. The grant applications and Emphasis Panel; NIDCR DSR Member
the discussions could disclose Conflict SEP.
DEPARTMENT OF HEALTH AND confidential trade secrets or commercial Date: June 5, 2018.
HUMAN SERVICES property such as patentable material, Time: 12:30 p.m. to 4:00 p.m.
and personal information concerning Agenda: To review and evaluate grant
National Institutes of Health individuals associated with the grant applications.
applications, the disclosure of which Place: National Institutes of Health, One
National Institute on Aging; Notice of Democracy Plaza, 6701 Democracy
would constitute a clearly unwarranted
Closed Meeting Boulevard, Bethesda, MD 20892 (Telephone
invasion of personal privacy. Conference Call).
Pursuant to section 10(d) of the Name of Committee: National Center for Contact Person: Marilyn Moore-Hoon,
Federal Advisory Committee Act, as Advancing Translational Sciences Special Ph.D., Scientific Review Officer, Scientific
amended, notice is hereby given of the Emphasis Panel; Tissue Chip Testing Center Review Branch, National Institute of Dental
(TCTC) & Data Centers (DC). and Craniofacial Research, 6701 Democracy
following meeting. Blvd., Rm. 676, Bethesda, MD 20892–4878,
Date: June 13, 2018.
The meeting will be closed to the Time: 8:00 a.m. to 5:00 p.m. 301–594–4861, mooremar@nidcr.nih.gov.
public in accordance with the Agenda: To review and evaluate grant Name of Committee: National Institute of
provisions set forth in sections applications. Dental and Craniofacial Research Special
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: National Institutes of Health, One Emphasis Panel; NIDCR Clinical Research
daltland on DSKBBV9HB2PROD with NOTICES

as amended. The contract proposals and Democracy Plaza, 6701 Democracy Grant Reviews.
the discussions could disclose Boulevard, Bethesda, MD 20892 (Telephone Date: June 6, 2018.
Conference Call). Time: 12:00 p.m. to 3:00 p.m.
confidential trade secrets or commercial Contact Person: Barbara J. Nelson, Ph.D., Agenda: To review and evaluate grant
property such as patentable material, Scientific Review Officer, Office of Scientific applications.
and personal information concerning Review, National Center for Advancing Place: National Institutes of Health, One
individuals associated with the contract Translational Sciences (NCATS), National Democracy Plaza, 6701 Democracy
proposals, the disclosure of which Institutes of Health 6701 Democracy Blvd., Boulevard, Bethesda, MD 20892.

VerDate Sep<11>2014 20:27 May 14, 2018 Jkt 244001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\15MYN1.SGM 15MYN1

Document Created: 2018-05-15 00:33:16
Document Modified: 2018-05-15 00:33:16

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		July 12, 2018.
FR Citation		83 FR 22501

83 FR 22501 - National Institute of General Medical Sciences; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 94 (May 15, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health